Genspera Inc (OTCMKTS:GNSZ) released its financial report for the quarter completed June 31, 2015 on August 6. Also, the company released the corporate update so as to highlight its extensive organizational and clinical development plans in the second quarter of 2015.
The buzz
Genspera continues to design unique concepts to envision, design, and advance innovative cancer treatments. Its advanced technology platform integrates a plant-derived cytotoxin and a prodrug delivery system that assists in targeted release of medication within tumors. The CEO Craig Dionne, Ph.D. said that the second quarter of this fiscal has been extremely busy and momentous for company’s future.
The management speaks
With remarkable Phase 2 clinical findings for hepatocellular carcinoma, and meeting and surpassing clinical objectives for underway Phase 2 glioblastoma trials which recorded increased patient enrollment, Genspera management is confident of the delivered mipsagargin value. The management looks forward to progress communications with major audiences.
The advancements
On July 16, 2015 the U.S. Court of Appeals provided a reason to Genspera to cheer about. The court ruled the ongoing case of company with Dr. Annastasiah Mhaka in favor of Genspera. Also, in a ‘per curiam order’, the Federal Circuit didn’t made any changes in the ruling of the U.S. District Court giving summary judgment in favor of the company in two consolidated proceedings related to the two patents of Genspera.
The district court gave a declaratory ruling that Dr. Mhaka will not be considered as a credited inventor in formulation of the two patents under discussion. Also, it granted summary verdict pertaining to state law tort allegations against the company and its two founders.
In last trading session, the share price of Genspera Inc (OTCMKTS:GNSZ) surged 0.35% to close the trading session at $0.850. The gains came at a share volume of 1.25 million compared to average monthly share volume of 96,820.
